- Home
- KLRS vs CIK Comparison
KLRS vs CIK Comparison
Compare KLRS & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CIK
- Stock Information
- Founded
- KLRS 2019
- CIK 1987
- Country
- KLRS United States
- CIK United States
- Employees
- KLRS N/A
- CIK N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CIK Finance/Investors Services
- Sector
- KLRS Health Care
- CIK Finance
- Exchange
- KLRS Nasdaq
- CIK Nasdaq
- Market Cap
- KLRS 129.0M
- CIK 154.6M
- IPO Year
- KLRS N/A
- CIK N/A
- Fundamental
- Price
- KLRS $2.40
- CIK $2.87
- Analyst Decision
- KLRS Buy
- CIK
- Analyst Count
- KLRS 1
- CIK 0
- Target Price
- KLRS N/A
- CIK N/A
- AVG Volume (30 Days)
- KLRS 46.4K
- CIK 115.4K
- Earning Date
- KLRS 08-15-2025
- CIK 01-01-0001
- Dividend Yield
- KLRS N/A
- CIK 9.03%
- EPS Growth
- KLRS N/A
- CIK N/A
- EPS
- KLRS N/A
- CIK N/A
- Revenue
- KLRS N/A
- CIK N/A
- Revenue This Year
- KLRS N/A
- CIK N/A
- Revenue Next Year
- KLRS N/A
- CIK N/A
- P/E Ratio
- KLRS N/A
- CIK N/A
- Revenue Growth
- KLRS N/A
- CIK N/A
- 52 Week Low
- KLRS $2.38
- CIK $2.50
- 52 Week High
- KLRS $24.15
- CIK $3.19
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- CIK 51.97
- Support Level
- KLRS N/A
- CIK $2.84
- Resistance Level
- KLRS N/A
- CIK $2.92
- Average True Range (ATR)
- KLRS 0.00
- CIK 0.03
- MACD
- KLRS 0.00
- CIK -0.00
- Stochastic Oscillator
- KLRS 0.00
- CIK 42.86
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.